Developer docs
API playgroundTry for free, no card

Search company profiles

Motilent

Full company profile

uuid0003jfk

Namestring
Motilent
Legal namestring
Motilent
Websiteurl
motilent.co.uk
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Motilent is a UK-based, privately held medical imaging software company founded in 2013 and headquartered in London, focused on gastrointestinal disease assessment. The company builds AI-powered computer vision tools that convert dynamic cine MRI sequences into quantitative motility scores, with its flagship GIQuant product providing a validated, regulator-cleared objective score for Crohn's disease activity in adults and children (CE marked Class IIa, FDA Cleared Class II). Beyond GIQuant, Motilent has assembled a four-product platform: Entrolytics, an end-to-end GI imaging workflow platform for ingest, storage, viewing, quantification, and communication; Bridge, an intestinal ultrasound capture and de-identification solution that feeds into Entrolytics; and vEUA, a 3D pelvic and perineal modelling tool built from MRI for surgical planning.

The company monetizes through software licensing to healthcare institutions (NHS hospitals, academic medical centers) and through clinical trial endpoint services to pharmaceutical companies, with revenue described as subscription/recurring in nature and pricing negotiated per institution or per study rather than publicly disclosed. Go-to-market is enterprise field sales, with strong distribution leverage from a £1.2 million NIHR grant awarded in May 2022 supporting NHS-wide deployment of GIQuant and a retrospective and prospective IBD study involving over 3,400 patients.

Strategically, Motilent operates a partnership-led model anchored by UCL and Professor Stuart Taylor for clinical validation, alongside a roster of major pharmaceutical collaborators including AstraZeneca, Takeda, Johnson & Johnson, Nestlé Health Science, Dr Falk Pharma, and VectivBio, and an international research network spanning pediatric hospitals in the US (Cincinnati Children's, Children's Hospital of Philadelphia) and European academic centers (KU Leuven, Inselspital, Aalborg University Hospital). Headcount is reported in the 11-50 range, no revenue has been publicly disclosed, and the company has not raised disclosed venture equity, relying instead on grants and accelerator participation (DigitalHealth.London, 2019) alongside non-dilutive institutional funding.

Short descriptiontext

Motilent is a UK-based medical imaging software company that uses AI-powered cine MRI analysis to deliver validated, regulator-cleared quantitative motility scores for Crohn's disease, serving NHS hospitals, academic medical centers, and pharmaceutical clinical trial sponsors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
gastrointestinal imaging software, medical imaging analysis, Crohn's disease quantification, MRI motility scoring, clinical trial imaging
Industry2 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code1 code
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Software Licensing
TypeSubscription Recurring
Description

Motilent generates revenue through licensing its medical imaging software (GIQuant, Entrolytics, Bridge, vEUA) to healthcare institutions including NHS hospitals, academic medical centers, and clinical research organizations. The software is deployed for both routine clinical practice and clinical trial applications.

motilent.io
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Entrolytics
Description

Secure, end-to-end medical imaging platform optimised for gastrointestinal data. Purpose-built for digestive disease combining clinical insight with multimodality data to support workflow - ingest, store, view, quantify, and communicate.

motilent.io
+3 more records
Core offering1 text field

Motilent develops and licenses medical imaging software for the gastrointestinal tract. Its flagship product GIQuant transforms subjective cine MRI sequences into a quantitative motility score for assessing Crohn's disease activity, and it is CE marked (Class IIa) and FDA Cleared (Class II) for adult and pediatric use. The portfolio also includes Entrolytics (an end-to-end GI imaging data platform), Bridge (intestinal ultrasound capture), and vEUA (3D pelvic/perineal modelling), sold to NHS hospitals, academic medical centres, pharmaceutical companies, and CROs for clinical practice and trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Transforms subjective cine MRI into quantitative motility score
+3 more records
Product overview1 text field

Motilent offers a multi-product platform for gastrointestinal imaging and analysis. The core portfolio consists of four products: GIQuant (quantitative MRI motility scoring for Crohn's disease), Entrolytics (unified medical imaging platform for GI data management and collaboration), Bridge (intestinal ultrasound data capture and storage), and vEUA (3D pelvic/perineal anatomy modelling from MRI). Entrolytics serves as the central data platform that integrates with Bridge, while GIQuant and vEUA are specialized analytical tools that process MRI data into actionable clinical outputs.

Product and service4 records
1GIQuant
CategoryMedical Imaging Software
Description

Software solution that transforms subjective cine MRI sequences into a quantitative motility score for the small bowel, providing a validated objective score quantifying Crohn's disease activity that can be tracked over time to support treatment decisions and clinical trials. CE marked (Class IIa) and FDA Cleared (Class II) for use in adults and children.

2Entrolytics
CategoryMedical Imaging Software
Description

Secure, end-to-end medical imaging platform optimised for gastrointestinal data that combines expert clinical insight with real-world multimodality data to support ingest, storage, viewing, quantification, and communication workflows for clinical practice, research, and clinical trials.

3Bridge
CategoryMedical Imaging Software
Description

Secure solution for capturing, storing, and sharing intestinal ultrasound (IUS) data that connects directly to ultrasound machines, automatically de-identifies patient data, and links to Entrolytics for compliant workflows supporting clinical trials, routine practice, and education.

4vEUA (Virtual Examination Under Anaesthetic)
CategoryMedical Imaging Software
Description

3D modelling technology for pelvic and perineal anatomy that enables clinicians to build an anatomically representative model of the sphincters, levator plate, and fistula tracts from MRI in under two minutes, providing clear, interactive visualisation for surgical planning, colleague collaboration, and patient communication.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical partner listed among Motilent's ecosystem partners, suggesting collaboration on clinical research or drug development support for gastrointestinal conditions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Major pharmaceutical company specializing in gastroenterology, partnered with Motilent for IBD research and clinical trial support.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Healthcare conglomerate partner engaged with Motilent in the gastrointestinal medical technology ecosystem.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Nutritional health company partner working with Motilent on gastrointestinal health solutions and research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic institution led by Professor Stuart Taylor, providing clinical validation and research collaboration for GIQuant technology. Academic radiologists from UCL contribute to product development and validation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Leading pediatric hospital partner collaborating on IBD research and pediatric applications of Motilent's imaging technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Major US pediatric hospital using Entrolytics for state-of-the-art IBD reporting and multi-centre clinical research collaboration.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Leading US pediatric hospital partner in the Motilent ecosystem for IBD research collaborations.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Belgian university with research partnership in gastrointestinal imaging and Motilent technology validation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Swiss university hospital partner in Motilent's international research network.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Pharmaceutical company specializing in gastroenterology, partner in Motilent's clinical research ecosystem.

12Fibrotarget
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partner focused on fibrostenosing Crohn's disease, aligned with Motilent's fibrostenotic Crohn's disease focus area.

motilent.io
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Biotechnology company focused on gastrointestinal diseases, partnered with Motilent for clinical research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

NHS foundation trust partner in UK healthcare research collaborations.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Intestinal ultrasound organization partner supporting IUS research and Bridge product applications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based medical-imaging AI company (also Oxford/London) developing quantitative MRI biomarkers for GI/hepatic conditions such as LiverMultiScan, sharing the same niche SaMD-plus-evidence commercialization model centered on pharma trial endpoints and NHS/US hospital deployment.

TypeDirect peer
Description

Valencia-based imaging-AI platform that builds CE/FDA-cleared quantitative radiology biomarkers sold to hospitals and pharma for trial endpoints, mirroring Motilent's regulatory-and-biomarker business model across multiple anatomies.

TypeDirect peer
Description

Radiology-AI vendor offering multi-modality clinical decision-support workflow software to hospitals and imaging centers, comparable as a workflow-anchored imaging AI vendor competing for similar PACS-integrated budgets.

TypeBroad incumbent
Description

Broad radiology-AI incumbent shipping dozens of FDA-cleared imaging algorithms into hospital PACS; represents the platform-incumbent risk Motilent faces and serves similar hospital enterprise buyers.

TypeBroad incumbent
Description

Specialty imaging-AI vendor (initially stroke, now broader) selling workflow and quantification modules to hospital systems — a similar 'specialty imaging biomarker sold into clinical workflow' commercial pattern to Motilent's.

TypeBroad incumbent
Description

FDA-cleared, workflow-embedded imaging-AI vendor monetized via per-hospital subscription; comparable for its regulatory + clinical-workflow commercial playbook even though its focus is neurovascular.

7contextvision
TypeBroad incumbent
Description

Swedish medical-imaging analysis vendor with a long track record of OEM image-quality software embedded into modalities, representing the broader medical-imaging-AI/embedded-software category Motilent sits within.

TypeEmerging player
Description

Earlier-stage imaging-AI player developing quantitative diffusion-MRI biomarkers for CNS indications, comparable as a smaller specialty imaging biomarker company leveraging AI for a specific clinical vertical.

TypeEmerging player
Description

European imaging-AI company focused on breast cancer screening workflows, sharing Motilent's profile of a UK/EU-based specialty SaMD vendor pursuing NHS and European hospital adoption with multi-modality ambitions.

TypeOthers
Description

Cloud-native imaging-AI platform (now part of Tempus) offering oncology and cardiac quantification; comparable as the cloud imaging-AI infrastructure ecosystem in which Motilent's Entrolytics platform competes and partners.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Motilent

Medical Imaging Softwaremotilent.co.uk

Motilent is a UK-based medical imaging software company that uses AI-powered cine MRI analysis to deliver validated, regulator-cleared quantitative motility scores for Crohn's disease, serving NHS hospitals, academic medical centers, and pharmaceutical clinical trial sponsors.

What Motilent does

Motilent is a UK-based, privately held medical imaging software company founded in 2013 and headquartered in London, focused on gastrointestinal disease assessment. The company builds AI-powered computer vision tools that convert dynamic cine MRI sequences into quantitative motility scores, with its flagship GIQuant product providing a validated, regulator-cleared objective score for Crohn's disease activity in adults and children (CE marked Class IIa, FDA Cleared Class II). Beyond GIQuant, Motilent has assembled a four-product platform: Entrolytics, an end-to-end GI imaging workflow platform for ingest, storage, viewing, quantification, and communication; Bridge, an intestinal ultrasound capture and de-identification solution that feeds into Entrolytics; and vEUA, a 3D pelvic and perineal modelling tool built from MRI for surgical planning.

The company monetizes through software licensing to healthcare institutions (NHS hospitals, academic medical centers) and through clinical trial endpoint services to pharmaceutical companies, with revenue described as subscription/recurring in nature and pricing negotiated per institution or per study rather than publicly disclosed. Go-to-market is enterprise field sales, with strong distribution leverage from a £1.2 million NIHR grant awarded in May 2022 supporting NHS-wide deployment of GIQuant and a retrospective and prospective IBD study involving over 3,400 patients.

Strategically, Motilent operates a partnership-led model anchored by UCL and Professor Stuart Taylor for clinical validation, alongside a roster of major pharmaceutical collaborators including AstraZeneca, Takeda, Johnson & Johnson, Nestlé Health Science, Dr Falk Pharma, and VectivBio, and an international research network spanning pediatric hospitals in the US (Cincinnati Children's, Children's Hospital of Philadelphia) and European academic centers (KU Leuven, Inselspital, Aalborg University Hospital). Headcount is reported in the 11-50 range, no revenue has been publicly disclosed, and the company has not raised disclosed venture equity, relying instead on grants and accelerator participation (DigitalHealth.London, 2019) alongside non-dilutive institutional funding.

Motilent firmographics

Firmographics
Name
Motilent
Legal name
Motilent
Website
https://motilent.co.uk
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Motilent is a UK-based medical imaging software company that uses AI-powered cine MRI analysis to deliver validated, regulator-cleared quantitative motility scores for Crohn's disease, serving NHS hospitals, academic medical centers, and pharmaceutical clinical trial sponsors.
Ownership category
akta.pro rank

Motilent industry classification

Industry
Product category
Medical Imaging Software
NAICS
Medical and Diagnostic Laboratories (62151)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Gastrointestinal imaging software
  • Medical imaging analysis
  • Crohn's disease quantification
  • MRI motility scoring
  • Clinical trial imaging

Where Motilent is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

Motilent business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Medical Software Licensing: Motilent generates revenue through licensing its medical imaging software (GIQuant, Entrolytics, Bridge, vEUA) to healthcare institutions including NHS hospitals, academic medical centers, and clinical research organizations. The software is deployed for both routine clinical practice and clinical trial applications.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Motilent product offering

Product offering

Core offering

Motilent develops and licenses medical imaging software for the gastrointestinal tract. Its flagship product GIQuant transforms subjective cine MRI sequences into a quantitative motility score for assessing Crohn's disease activity, and it is CE marked (Class IIa) and FDA Cleared (Class II) for adult and pediatric use. The portfolio also includes Entrolytics (an end-to-end GI imaging data platform), Bridge (intestinal ultrasound capture), and vEUA (3D pelvic/perineal modelling), sold to NHS hospitals, academic medical centres, pharmaceutical companies, and CROs for clinical practice and trials.

Product overview

Motilent offers a multi-product platform for gastrointestinal imaging and analysis. The core portfolio consists of four products: GIQuant (quantitative MRI motility scoring for Crohn's disease), Entrolytics (unified medical imaging platform for GI data management and collaboration), Bridge (intestinal ultrasound data capture and storage), and vEUA (3D pelvic/perineal anatomy modelling from MRI). Entrolytics serves as the central data platform that integrates with Bridge, while GIQuant and vEUA are specialized analytical tools that process MRI data into actionable clinical outputs.

Differentiator

Problem solved

Functional benefit

Brands

  • Entrolytics: Secure, end-to-end medical imaging platform optimised for gastrointestinal data. Purpose-built for digestive disease combining clinical insight with multimodality data to support workflow - ingest, store, view, quantify, and communicate.
  • GIQuant
  • Bridge
  • vEUA

Products and services

  • GIQuant Software solution that transforms subjective cine MRI sequences into a quantitative motility score for the small bowel, providing a validated objective score quantifying Crohn's disease activity that can be tracked over time to support treatment decisions and clinical trials. CE marked (Class IIa) and FDA Cleared (Class II) for use in adults and children.
  • Entrolytics Secure, end-to-end medical imaging platform optimised for gastrointestinal data that combines expert clinical insight with real-world multimodality data to support ingest, storage, viewing, quantification, and communication workflows for clinical practice, research, and clinical trials.
  • Bridge Secure solution for capturing, storing, and sharing intestinal ultrasound (IUS) data that connects directly to ultrasound machines, automatically de-identifies patient data, and links to Entrolytics for compliant workflows supporting clinical trials, routine practice, and education.
  • vEUA (Virtual Examination Under Anaesthetic) 3D modelling technology for pelvic and perineal anatomy that enables clinicians to build an anatomically representative model of the sphincters, levator plate, and fistula tracts from MRI in under two minutes, providing clear, interactive visualisation for surgical planning, colleague collaboration, and patient communication.

Quantifiable outcome

  • Transforms subjective cine MRI into quantitative motility score
  • +3 more outcomes

Companies that use Motilent

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Motilent technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Motilent partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core and minor.

  • AstraZenecacoreStrategic or Co-development PartnerPharmaceutical partner listed among Motilent's ecosystem partners, suggesting collaboration on clinical research or drug development support for gastrointestinal conditions.
  • TakedacoreStrategic or Co-development PartnerMajor pharmaceutical company specializing in gastroenterology, partnered with Motilent for IBD research and clinical trial support.
  • Johnson & JohnsoncoreStrategic or Co-development PartnerHealthcare conglomerate partner engaged with Motilent in the gastrointestinal medical technology ecosystem.
  • Nestlé Health SciencecoreStrategic or Co-development PartnerNutritional health company partner working with Motilent on gastrointestinal health solutions and research.
  • UCL (University College London)coreStrategic or Co-development PartnerAcademic institution led by Professor Stuart Taylor, providing clinical validation and research collaboration for GIQuant technology. Academic radiologists from UCL contribute to product development and validation.
  • Great Ormond Street HospitalminorStrategic or Co-development PartnerLeading pediatric hospital partner collaborating on IBD research and pediatric applications of Motilent's imaging technology.
  • Cincinnati Children's HospitalminorStrategic or Co-development PartnerMajor US pediatric hospital using Entrolytics for state-of-the-art IBD reporting and multi-centre clinical research collaboration.
  • Children's Hospital of PhiladelphiaminorStrategic or Co-development PartnerLeading US pediatric hospital partner in the Motilent ecosystem for IBD research collaborations.
  • KU LeuvenminorStrategic or Co-development PartnerBelgian university with research partnership in gastrointestinal imaging and Motilent technology validation.
  • Inselspital (Bern University Hospital)minorStrategic or Co-development PartnerSwiss university hospital partner in Motilent's international research network.
  • Dr Falk PharmaminorStrategic or Co-development PartnerPharmaceutical company specializing in gastroenterology, partner in Motilent's clinical research ecosystem.
  • FibrotargetminorStrategic or Co-development PartnerResearch partner focused on fibrostenosing Crohn's disease, aligned with Motilent's fibrostenotic Crohn's disease focus area.
  • VectivBiominorStrategic or Co-development PartnerBiotechnology company focused on gastrointestinal diseases, partnered with Motilent for clinical research.
  • CUH (Cambridge University Hospitals)minorStrategic or Co-development PartnerNHS foundation trust partner in UK healthcare research collaborations.
  • IBUSminorStrategic or Co-development PartnerIntestinal ultrasound organization partner supporting IUS research and Bridge product applications.

Scale indicators2 records

Recent moves6 records

Expansion highlights7 records

Motilent competitors and assessment

Company assessment

Direct peers

  • Perspectum: UK-based medical-imaging AI company (also Oxford/London) developing quantitative MRI biomarkers for GI/hepatic conditions such as LiverMultiScan, sharing the same niche SaMD-plus-evidence commercialization model centered on pharma trial endpoints and NHS/US hospital deployment.
  • Quibim: Valencia-based imaging-AI platform that builds CE/FDA-cleared quantitative radiology biomarkers sold to hospitals and pharma for trial endpoints, mirroring Motilent's regulatory-and-biomarker business model across multiple anatomies.
  • Annalise.ai: Radiology-AI vendor offering multi-modality clinical decision-support workflow software to hospitals and imaging centers, comparable as a workflow-anchored imaging AI vendor competing for similar PACS-integrated budgets.

Broad incumbents

  • Aidoc: Broad radiology-AI incumbent shipping dozens of FDA-cleared imaging algorithms into hospital PACS; represents the platform-incumbent risk Motilent faces and serves similar hospital enterprise buyers.
  • RapidAI: Specialty imaging-AI vendor (initially stroke, now broader) selling workflow and quantification modules to hospital systems — a similar 'specialty imaging biomarker sold into clinical workflow' commercial pattern to Motilent's.
  • Viz.ai: FDA-cleared, workflow-embedded imaging-AI vendor monetized via per-hospital subscription; comparable for its regulatory + clinical-workflow commercial playbook even though its focus is neurovascular.
  • contextvision: Swedish medical-imaging analysis vendor with a long track record of OEM image-quality software embedded into modalities, representing the broader medical-imaging-AI/embedded-software category Motilent sits within.

Emerging players

  • Imeka: Earlier-stage imaging-AI player developing quantitative diffusion-MRI biomarkers for CNS indications, comparable as a smaller specialty imaging biomarker company leveraging AI for a specific clinical vertical.
  • Kheiron Medical Technologies: European imaging-AI company focused on breast cancer screening workflows, sharing Motilent's profile of a UK/EU-based specialty SaMD vendor pursuing NHS and European hospital adoption with multi-modality ambitions.

Others

  • Arterys (Tempus): Cloud-native imaging-AI platform (now part of Tempus) offering oncology and cardiac quantification; comparable as the cloud imaging-AI infrastructure ecosystem in which Motilent's Entrolytics platform competes and partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

Motilent social profiles

Digital presence

Motilent compliance and trust

Trust signal

Compliance2 records

Motilent financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Motilent leadership team

Management profile

Number of profiles

Profiles1 record

Motilent funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Motilent M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Motilent

What does Motilent do?

Motilent develops and licenses medical imaging software for the gastrointestinal tract. Its flagship product GIQuant transforms subjective cine MRI sequences into a quantitative motility score for assessing Crohn's disease activity, and it is CE marked (Class IIa) and FDA Cleared (Class II) for adult and pediatric use. The portfolio also includes Entrolytics (an end-to-end GI imaging data platform), Bridge (intestinal ultrasound capture), and vEUA (3D pelvic/perineal modelling), sold to NHS hospitals, academic medical centres, pharmaceutical companies, and CROs for clinical practice and trials.

Is Motilent a public or private company?

Motilent is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Motilent founded?

Motilent was founded in 2013. It employs 11 to 50 people.

Where is Motilent based?

Motilent is headquartered in London, United Kingdom, in the Europe region.

How does Motilent make money?

One revenue line is on record: medical Software Licensing.

Who are Motilent's main competitors?

Direct peers on record are Perspectum, Quibim and Annalise.ai. Broad incumbents are Aidoc, RapidAI, Viz.ai and contextvision. Emerging players are Imeka and Kheiron Medical Technologies. Arterys (Tempus) is listed as an others.

Does Motilent have an API?

No public API is recorded for Motilent.

What industry is Motilent in?

Motilent's product category is Medical Imaging Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software. Its NAICS code is 62151 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tech Funding NewsMotilent raises £1.2M to rollout its CE-marked GIQuant software — TFNUK-based Motilent has secured £1.2 million in funding from the National Institute for Health and Care Research (NIHR) to deploy its CE-marked AI software, GIQuant, across more than 10 NHS hospitals. The investment supports a prospective study involving over 3,400 patients to evaluate the technology's impact on managing Inflammatory Bowel Disease and Crohn’s Disease. This rollout aims to provide clinicians with objective data to monitor treatment responses and improve patient care workflows.BusinessCloudAI imaging to help treat Crohn’s Disease in UK hospitalsMotilent raised £1.2 million from the NIHR to roll out its AI imaging software GIQuant into over 10 UK hospitals. The tech analyzes MRI scans to track bowel motility, aiding Crohn's disease treatment decisions. The funding supports a retrospective study and prospective research across 3,400 patients.PR NewswireAI gut-imaging software takes on the US with FDA clearance and national hospital partnershipMotilent, a UK-based AI medical imaging company specializing in digestive disease assessment, has received FDA 510K clearance for its GIQuant software, enabling deployment in the US healthcare market. The clearance will be executed through a partnership with Nuance AI, whose solutions are used by 90% of US hospitals and 80% of US radiologists, providing clinicians with motility data from routine MRI scans to monitor Crohn's disease treatment response. The company will showcase its technology at RSNA 2021 as part of its US market launch targeting the 62 million Americans affected by digestive diseases.